2025-11-23 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided data.

**Report: Johnson & Johnson (JNJ) Analysis**

**Company Overview:** Johnson & Johnson is a global healthcare company that develops, manufactures, and sells a broad range of products in the healthcare field.

**1. Performance vs. S&P 500 (VOO)**

*   **JNJ Cumulative Return:** 56.61%
*   **VOO Cumulative Return:** 94.64%
*   **Tracking Difference:** -48.0%
*   **Relative Spread:** 21.2 (Indicates that the current spread is in the lower range of its historical spread relative to VOO)

*Analysis:* JNJ has significantly underperformed the S&P 500 (VOO) over the period considered. The relative spread suggests that this underperformance is closer to the historical minimum difference between JNJ and VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha  | Beta | Cap(B) |
| ---------- | ------- | ------- | ------ | ---- | ------ |
| 2015-2017  | 26.0%   | 66.8%   | -2.0%  | 0.0  | 336.6  |
| 2016-2018  | 14.0%   | 10.7%   | -1.0%  | 0.1  | 310.9  |
| 2017-2019  | 20.0%   | 71.5%   | -2.0%  | 0.4  | 351.4  |
| 2018-2020  | 19.0%   | 79.2%   | -4.0%  | 0.4  | 379.2  |
| 2019-2021  | 33.0%   | 79.2%   | -14.0% | 0.5  | 412.2  |
| 2020-2022  | 8.0%    | 79.6%   | 9.0%   | 0.4  | 425.6  |
| 2021-2023  | -19.0%  | 79.6%   | -21.0% | 0.3  | 377.6  |
| 2022-2024  | -32.0%  | 79.6%   | -53.0% | 0.3  | 348.4  |
| 2023-2025  | 28.0%   | 79.6%   | -32.0% | 0.1  | 491.3  |

*Analysis:*

*   **CAGR (Compound Annual Growth Rate):** Fluctuates significantly, showing periods of strong growth and contraction.
*   **MDD (Maximum Drawdown):** Consistently high, indicating significant potential for losses during downturns.
*   **Alpha:** Mostly negative, meaning JNJ has generally underperformed its benchmark on a risk-adjusted basis. Recent years show more significant negative alpha.
*   **Beta:** Low, suggesting JNJ is less volatile than the overall market.
*   **Cap(B) Market Capitalization:**  The company's market capitalization shows overall growth, though it has seen pullbacks in certain periods.

**2. Recent Price Action**

*   **Current Price:** 203.9
*   **Previous Close:** 203.07
*   **Price Change:** 0.41
*   **5-Day Moving Average:** 201.812
*   **20-Day Moving Average:** 192.4328
*   **60-Day Moving Average:** 186.4627

*Analysis:* The current price is above the 5, 20, and 60-day moving averages, suggesting an upward trend in the short to medium term. The positive price change relative to the previous close reinforces this.

**3. Market Risk Indicators and Expected Return**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment Recommended)
*   **RSI (Relative Strength Index):** 96.52 (Overbought)
*   **PPO (Percentage Price Oscillator):** 0.6583
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (5 shares - Very Safe - MRI:0.90)
*   **20-Day Relative Spread Change:** 8.3% (Positive - Short-term Increase)
*   **Expected Return:** -82.9% (Long-term underperformance vs. S&P 500 if investing now)

*Analysis:*

*   The RSI indicates the stock is overbought, which could suggest a potential pullback.
*   The positive change in relative spread aligns with the recent price increase.
*   The very negative expected return is a major concern, suggesting the stock is currently overvalued or has poor long-term growth prospects relative to the broader market.
*   The Hybrid Signal suggests a buying opportunity.

**4. Recent News & Significant Events**

*   **Positive Sentiment:**
    *   Jim Cramer's positive view on Kenvue (J&J spin-off).
    *   Articles highlighting positive developments and reasons for stock surge.
    *   Healthcare ETFs integrating AI (potential tailwind for J&J).
*   **Negative/Neutral News:**
    *   Contineum's MS drug trial failure.
    *   Eli Lilly's market cap milestone (highlights competition).

*Analysis:* Recent news presents a mixed picture. While there are positive articles and potential tailwinds (AI in healthcare), a failed drug trial is a setback.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.16)
*   **Target Price:** Average: $200.82, High: $230.00, Low: $155.00

*Analysis:* Analyst consensus is generally positive, though the current price is above the average target price, suggesting limited immediate upside.

**5. Recent Earnings Analysis:**

| Date       | EPS  | Revenue    |
| ---------- | ---- | ---------- |
| 2025-10-22 | 2.14 | $23.99 B  |
| 2025-07-24 | 2.3  | $23.74 B  |
| 2025-04-23 | 4.57 | $21.89 B  |
| 2024-10-23 | 1.12 | $22.47 B  |
| 2025-10-22 | 1.12 | $22.47 B  |

*Analysis:* The most recent EPS and revenue figures show mixed results. While revenue has been relatively consistent, EPS has fluctuated significantly. The $4.57 EPS figure in 2025-04-23 stands out.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
| ---------- | ---------- | ------------- |
| 2025-09-30 | $23.99B   | 69.56%        |
| 2025-06-30 | $23.74B   | 67.87%        |
| 2025-03-31 | $21.89B   | 66.40%        |
| 2024-12-31 | $22.52B   | 68.35%        |
| 2024-09-30 | $22.47B   | 69.01%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE  |
| ---------- | ---------- | ---- |
| 2025-09-30 | $79.28B   | 6.50% |
| 2025-06-30 | $78.47B   | 7.06% |
| 2025-03-31 | $78.11B   | 14.08% |
| 2024-12-31 | $71.49B   | 4.80% |
| 2024-09-30 | $70.16B   | 3.84% |

*Analysis:*

*   **Revenue:**  Relatively stable revenue over the last five quarters.
*   **Profit Margin:** Strong and consistent profit margins, indicating efficient operations.
*   **Equity:**  Steady growth in equity over the period.
*   **ROE (Return on Equity):**  ROE has fluctuated, with a high in Q1 2025.

**7. Overall Analysis**

*   **Underperformance:** JNJ has significantly underperformed the S&P 500, and the expected return suggests continued underperformance.
*   **Mixed Signals:** While the stock shows short-term upward momentum (price above moving averages, positive spread change), the overbought RSI and negative expected return raise concerns.
*   **Analyst Opinion:** Analysts generally have a positive outlook, but the current price is near or above the average target.
*   **Financial Health:**  JNJ maintains strong revenue, profit margins, and growing equity.
*   **News Impact:** Recent news flow is mixed.

**Conclusion:**

Based on the provided data, Johnson & Johnson presents a mixed investment profile. While it has a history of stability and strong financial metrics, its recent underperformance relative to the S&P 500 and concerning expected return warrant caution. The overbought RSI suggests a potential near-term pullback. Investors should carefully weigh these factors and conduct further research before making an investment decision.
